These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32975710)

  • 1. The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review.
    Cheng AYY; Wong J; Freemantle N; Acharya SH; Ekinci E
    Diabetes Ther; 2020 Nov; 11(11):2555-2593. PubMed ID: 32975710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.
    Woo VC
    Clin Ther; 2017 Aug; 39(8S2):S12-S33. PubMed ID: 28187863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV; Paschos P; Karagiannis T; Katsoula A; Athanasiadou E; Kitsios K; Bekiari E; Matthews DR; Tsapas A
    Ann Intern Med; 2018 Aug; 169(3):165-174. PubMed ID: 29987326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues.
    Cheng A; Bailey TS; Mauricio D; Roussel R
    Diabetes Metab Res Rev; 2020 Oct; 36(7):e3329. PubMed ID: 32315508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review.
    Ghosh S; Kalra S; Bantwal G; Sahay RK
    Curr Diabetes Rev; 2023; 19(9):e090123212447. PubMed ID: 36624651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.
    Bilal A; Pratley RE
    Curr Diab Rep; 2018 Sep; 18(11):102. PubMed ID: 30229352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs.
    D'Souza SC; Kruger DF
    Diabetes Ther; 2020 Dec; 11(12):2775-2790. PubMed ID: 33000382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.
    Dżygało K; Golicki D; Kowalska A; Szypowska A
    Acta Diabetol; 2015 Apr; 52(2):231-8. PubMed ID: 25430705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Zhou W; Tao J; Zhou X; Chen H
    Diabetes Ther; 2019 Jun; 10(3):835-852. PubMed ID: 31020539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal.
    Hernando VU; Pablo FJ
    Diabetes Metab Syndr; 2019; 13(3):2126-2141. PubMed ID: 31235147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study.
    Bjekić-Macut J; Živković TB; Kocić R
    Diabetes Ther; 2018 Apr; 9(2):651-662. PubMed ID: 29460260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New generation of insulins: glargine U300. Summary of clinical evidence].
    Musso C; Capurro L; Mingote E; Forti L; Guaita MS
    Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G; Strange P
    Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.